CD20 expression by immunohistochemistry

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`BIO-CD20-IHC`
Type	Biomarker
Aliases	CD20CD20 expression (IHC)Експресія CD20 (імуногістохімія)
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Biomarker Facts

Biomarker type	protein_expression_ihc
Measurement	MethodImmunohistochemistry on FFPE tissue (anti-CD20 antibody, e.g., L26 clone) Unitscategorical (positive \| negative \| weak/equivocal)
Related biomarkers	None declared

Notes

CD20+ status is required for any anti-CD20 monoclonal antibody therapy (rituximab, obinutuzumab). Most B-cell lymphomas are CD20+; rare exceptions (some HHV-8+ neoplasms, certain plasmablastic lymphomas) may be CD20- and require alternative regimens. Status can change post-rituximab — re-biopsy on relapse.

Used By

Indications

IND-BURKITT-1L-CODOXM-IVAC - IND-BURKITT-1L-CODOXM-IVAC
IND-BURKITT-1L-DAEPOCHR - IND-BURKITT-1L-DAEPOCHR
IND-BURKITT-1L-HYPERCVAD-R - IND-BURKITT-1L-HYPERCVAD-R
IND-BURKITT-2L-RDHAP-ASCT - IND-BURKITT-2L-RDHAP-ASCT
IND-BURKITT-2L-RICE-ASCT - IND-BURKITT-2L-RICE-ASCT
IND-CHL-PREGNANCY-MOD-ABVD - IND-CHL-PREGNANCY-MOD-ABVD
IND-CLL-3L-LISOCEL - IND-CLL-3L-LISOCEL
IND-DLBCL-1L-POLA-R-CHP - IND-DLBCL-1L-POLA-R-CHP
IND-DLBCL-1L-RCHOP - IND-DLBCL-1L-RCHOP
IND-DLBCL-1L-RCHOP-ISRT-EARLY - IND-DLBCL-1L-RCHOP-ISRT-EARLY
IND-DLBCL-2L-LISOCEL - IND-DLBCL-2L-LISOCEL
IND-DLBCL-2L-POLA-R-BENDAMUSTINE - IND-DLBCL-2L-POLA-R-BENDAMUSTINE
IND-DLBCL-3L-AXICEL-CART - IND-DLBCL-3L-AXICEL-CART
IND-DLBCL-3L-EPCORITAMAB - IND-DLBCL-3L-EPCORITAMAB
IND-DLBCL-3L-GLOFITAMAB - IND-DLBCL-3L-GLOFITAMAB
IND-DLBCL-3L-LISO-CEL-CART - IND-DLBCL-3L-LISO-CEL-CART
IND-DLBCL-3L-LONCASTUXIMAB - IND-DLBCL-3L-LONCASTUXIMAB
IND-DLBCL-RENAL-FAILURE-MOD-RCHOP - IND-DLBCL-RENAL-FAILURE-MOD-RCHOP
IND-FL-1L-BR - IND-FL-1L-BR
IND-FL-1L-RCHOP-AGGRESSIVE - IND-FL-1L-RCHOP-AGGRESSIVE
IND-FL-1L-WATCH - IND-FL-1L-WATCH
IND-FL-3L-AXICEL-CART - IND-FL-3L-AXICEL-CART
IND-FL-3L-MOSUNETUZUMAB - IND-FL-3L-MOSUNETUZUMAB
IND-FL-POST-INDUCTION-RITUXIMAB-MAINTENANCE - IND-FL-POST-INDUCTION-RITUXIMAB-MAINTENANCE
IND-HGBL-DH-1L-DAEPOCHR - IND-HGBL-DH-1L-DAEPOCHR
IND-HGBL-DH-1L-RCHOP - IND-HGBL-DH-1L-RCHOP
IND-HGBL-DH-2L-CART-AXICEL - IND-HGBL-DH-2L-CART-AXICEL
IND-MCL-1L-BTKI-R - IND-MCL-1L-BTKI-R
IND-MCL-1L-INTENSIVE - IND-MCL-1L-INTENSIVE
IND-MCL-3L-BREXUCEL-CART - IND-MCL-3L-BREXUCEL-CART
IND-MCL-3L-LISOCEL - IND-MCL-3L-LISOCEL
IND-MCL-POST-INDUCTION-RITUXIMAB-MAINTENANCE - IND-MCL-POST-INDUCTION-RITUXIMAB-MAINTENANCE
IND-NLPBL-1L-OBSERVATION-OR-RT - IND-NLPBL-1L-OBSERVATION-OR-RT
IND-NLPBL-1L-RITUXIMAB-MONO - IND-NLPBL-1L-RITUXIMAB-MONO
IND-NLPBL-2L-RCHOP-TRANSFORMATION - IND-NLPBL-2L-RCHOP-TRANSFORMATION
IND-NMZL-1L-BR - IND-NMZL-1L-BR
IND-NMZL-1L-HCV-POSITIVE - IND-NMZL-1L-HCV-POSITIVE
IND-NMZL-1L-WATCH - IND-NMZL-1L-WATCH
IND-NMZL-2L-BR - IND-NMZL-2L-BR
IND-PCNSL-1L-MATRIX - IND-PCNSL-1L-MATRIX
... 9 more

Questionnaires

QUEST-BURKITT-1L-STUB - Burkitt Lymphoma — first line
QUEST-CHL-1L-STUB - Classical Hodgkin Lymphoma — first line
QUEST-DLBCL-NOS-1L-STUB - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — first line
QUEST-FL-1L-STUB - Follicular Lymphoma — first line
QUEST-HGBL-DH-1L-STUB - High-Grade B-Cell Lymphoma, Double-Hit / Triple-Hit — first line
QUEST-MCL-1L-STUB - Mantle Cell Lymphoma — first line
QUEST-NLPBL-1L-STUB - Nodular Lymphocyte-Predominant B-cell Lymphoma — first line
QUEST-NODAL-MZL-1L-STUB - Nodal Marginal Zone Lymphoma — first line
QUEST-PCNSL-1L-STUB - Primary CNS Lymphoma — first line
QUEST-PMBCL-1L-STUB - Primary Mediastinal Large B-Cell Lymphoma — first line
QUEST-PTLD-1L-STUB - Post-Transplant Lymphoproliferative Disorder — first line
QUEST-SPLENIC-MZL-1L-STUB - Splenic Marginal Zone Lymphoma — first line